KMT2A and acute lymphoblastic leukemia: Therefore, we believe that combination treatment of the multiple kinase inhibitor RK-20449 and the Bcl-2 inhibitor ABT-199 overcomes GC-resistance in MLL-ALL, offering a new effective therapeutic strategy for this high-risk disease.